Lung cancer ranks as the second most frequently diagnosed cancer in both men and women. It is also the leading cause of cancer-related deaths globally, resulting in approximately 1.8 million deaths annually. Lung cancer can be classified into two primary categories depending on their morphological forms: non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC). Many patients are diagnosed with lung cancer in the advanced stages of the disease, which rules out surgery as an effective option. Instead, they rely solely on radiotherapy or chemotherapy for treatment. However, the effectiveness of these treatments has been limited, prompting the need to explore alternative preventive strategies.  Targeting the tumor microenvironment is one of the most successful treatment approaches for lung cancer. The recent emergence of immune checkpoint inhibitors (ICIs), such as monoclonal antibodies targeting CTLA-4 and PD-1 and its ligand PD-L1, has been shown to be effective.  These special issues aim to showcase some recent advancements in targeted therapies and immunotherapy, with the goal of enhancing treatment outcomes for patients with lung cancer.

Author registration and submission: https://accscience.com/user/login. Submit your paper along with a cover letter, including the special issue title. Your paper will undergo a fair peer review and be published immediately after acceptance and will be available to an international audience.